NeurAxis, Inc. (NRXS)

NeurAxis, Inc. stock has experienced significant positive momentum over the past year. Key events impacting the stock price include strong financial results, FDA clearance for treating pain in Functional Dyspepsia, academic society guidelines recommending PENFS for Functional Abdominal Pain, expanded FDA clearance for IB-Stim, the assignment of a new CPT Category I code for PENFS procedures, significant new medical policy coverage, and additional health insurers providing medical policy coverage for PENFS.

The provided search results do not contain explicit information about the demand seasonality for NeurAxis, Inc.'s products and services. Demand for its neuromodulation therapies might be relatively stable throughout the year, as these are ongoing conditions rather than seasonal ailments.

NeurAxis, Inc. is a medical technology company specializing in neuromodulation therapies for chronic conditions. Their core product, IB-Stim, is FDA-cleared for treating functional abdominal pain associated with IBS, functional dyspepsia, and FD-related nausea in patients aged 8 years and older. The company also offers a rectal expulsion device (RED).

NeurAxis, Inc. primarily focuses on the United States. The company's corporate offices are located in Carmel, Indiana, and it has a distribution center in Batesville, Indiana.

NeurAxis's brand reputation has been positively influenced by FDA clearances, academic society guidelines, the implementation of a Category I CPT code, expanded payer coverage, and revenue growth. These achievements have bolstered its reputation as an innovator in neuromodulation therapies.

NeurAxis, Inc. has 21 institutional owners and shareholders. Major institutional shareholders include AIGH Capital Management LLC, Rosalind Advisors, Inc., and Money Concepts Capital Corp. In the past three months, NeurAxis insiders have bought more company stock than they have sold.